Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE)
2021 · EClinicalMedicine · 36 citations
https://doi.org/10.1016/j.eclinm.2021.101086
C
Cristina Ferreras
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
51
Papers
766
Citations
14
h-index
20
i10-index
Cristina Ferreras is an academic researcher from Venter Pharma (Spain). The author has contributed to research in topics: CAR-T cell therapy research & SARS-CoV-2 and COVID-19 Research & Immune Cell Function and Interaction. The author has an h-index of 14, co-authored 44 publications.
ORCID: 0000-0001-9595-4998Papers by this author
worksOptimizing the Procedure to Manufacture Clinical-Grade NK Cells for Adoptive Immunotherapy
2021 · Cancers · 30 citations
https://doi.org/10.3390/cancers13030577
Phase 2 Clinical Trial of Infusing Haploidentical K562-mb15-41BBL–Activated and Expanded Natural Killer Cells as Consolidation Therapy for Pediatric Acute Myeloblastic Leukemia
2021 · Clinical Lymphoma Myeloma & Leukemia · 18 citations
https://doi.org/10.1016/j.clml.2021.01.013
A phase I/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol
2021 · Trials · 12 citations
https://doi.org/10.1186/s13063-021-05625-7
Two Congenital Gastrointestinal Malformations: A Case of Omphalocele and Meckel’s Diverticulum in a Neonate
2024 · Cureus · 1 citations
https://doi.org/10.7759/cureus.62603
Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity
2021 · Figshare · 0 citations
https://doi.org/10.6084/m9.figshare.14161995
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat